Skip to main content
Premium Trial:

Request an Annual Quote

HTS Biosystems to Open Asian Office

NEW YORK, May 29 – HTS Biosystems announced Tuesday plans to establish an office in Yokohama, Japan in its effort to grow its proteomics business in the Asian market.

HTS of Hopkinton, Mass., has appointed Masaaki Sasajima as vice president of Asian Operations and head of HTS Asia.

Sasajima, who previously worked for the life science and diagnostics unit of Mitsubishi Chemical, will be in charge of developing the company’s business in Asia and managing its relationship with Mitsubishi Chemical, which has exclusive rights to distribute HTS’s surface plasmon resonance technology in Japan.

“Mr. Sasajima's longstanding experience in biotechnology and worldwide operations will be crucial as we promote the company and our core technology in Asia,” Greg Freitag, CEO of HTS Biosystems, said in a statement. “Asia represents an important long-term business opportunity and a significant source of revenue.”

Sasajima and Mitsubishi will also collaborate on technological enhancements regarding chip chemistries and advanced chip structures that will improve manufacturability of chips and performance of the company’s Flex Chip Kinetic Analysis System. The company previously said it plans to introduce the Flex Chip, its first product, in the second half of next year. The Flex Chip system uses HTS proprietary technology to enable real-time detection of biomolecular events without reporter labels.

Freitag was not immediately available for comment.

HTS is 73 percent owned by Minnesota-based Quantech and 18 percent owned by Applied Biosystems.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.